JP2018510881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510881A5 JP2018510881A5 JP2017550603A JP2017550603A JP2018510881A5 JP 2018510881 A5 JP2018510881 A5 JP 2018510881A5 JP 2017550603 A JP2017550603 A JP 2017550603A JP 2017550603 A JP2017550603 A JP 2017550603A JP 2018510881 A5 JP2018510881 A5 JP 2018510881A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- cells
- monoclonal antibody
- combined therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139258P | 2015-03-27 | 2015-03-27 | |
| US62/139,258 | 2015-03-27 | ||
| PCT/US2016/024318 WO2016160602A2 (en) | 2015-03-27 | 2016-03-25 | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133495A Division JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510881A JP2018510881A (ja) | 2018-04-19 |
| JP2018510881A5 true JP2018510881A5 (https=) | 2019-05-09 |
| JP6748105B2 JP6748105B2 (ja) | 2020-08-26 |
Family
ID=57006343
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550603A Active JP6748105B2 (ja) | 2015-03-27 | 2016-03-25 | がん治療のための遺伝子改変ｎｋ−９２細胞およびモノクローナル抗体 |
| JP2020133495A Active JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2021208864A Active JP7328314B2 (ja) | 2015-03-27 | 2021-12-23 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2023126658A Active JP7557704B2 (ja) | 2015-03-27 | 2023-08-03 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2024146060A Active JP7766151B2 (ja) | 2015-03-27 | 2024-08-28 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2025180073A Pending JP2026021400A (ja) | 2015-03-27 | 2025-10-27 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133495A Active JP7000512B2 (ja) | 2015-03-27 | 2020-08-06 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2021208864A Active JP7328314B2 (ja) | 2015-03-27 | 2021-12-23 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2023126658A Active JP7557704B2 (ja) | 2015-03-27 | 2023-08-03 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2024146060A Active JP7766151B2 (ja) | 2015-03-27 | 2024-08-28 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
| JP2025180073A Pending JP2026021400A (ja) | 2015-03-27 | 2025-10-27 | がん治療のための遺伝子改変ｎｋ－９２細胞およびモノクローナル抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10456420B2 (https=) |
| EP (1) | EP3273993A4 (https=) |
| JP (6) | JP6748105B2 (https=) |
| KR (3) | KR102751730B1 (https=) |
| CN (4) | CN117379460A (https=) |
| AU (3) | AU2016243120B2 (https=) |
| CA (1) | CA2977423A1 (https=) |
| HK (2) | HK1249854A1 (https=) |
| IL (4) | IL287051B (https=) |
| WO (1) | WO2016160602A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117379460A (zh) | 2015-03-27 | 2024-01-12 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| JP7178906B2 (ja) | 2016-05-19 | 2022-11-28 | ザ ジェネラル ホスピタル コーポレイション | ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ |
| CA3042238C (en) * | 2016-10-28 | 2021-08-10 | Nant Holdings Ip, Llc | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| US20180221463A1 (en) * | 2017-01-13 | 2018-08-09 | The Chinese University Of Hong Kong | Modified NK Cells and Uses Thereof |
| US10801013B2 (en) * | 2017-03-08 | 2020-10-13 | Nantkwest, Inc. | Modified NK-92 haNK003 cells for the clinic |
| AU2018265534A1 (en) * | 2017-05-11 | 2019-10-31 | Nantkwest, Inc. | Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment |
| KR20220068272A (ko) | 2017-08-15 | 2022-05-25 | 난트셀, 인크. | Hank 세툭시맙 조합 및 방법 |
| US20190321402A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
| CN108531458A (zh) * | 2018-04-27 | 2018-09-14 | 赛诺（深圳）生物医药研究有限公司 | 治疗肿瘤的基因工程自然杀伤细胞产品 |
| WO2020014245A1 (en) | 2018-07-10 | 2020-01-16 | Nantkwest, Inc. | Cryopreservation |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| EP3847242A4 (en) | 2018-09-07 | 2022-06-08 | NantBio, Inc. | TARGETED IL-12 TREATMENTS AND METHODS TO STIMULATE HANK AND NK92MI CELLS |
| KR102533540B1 (ko) * | 2018-10-31 | 2023-05-17 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells) |
| EP3743512A4 (en) * | 2018-10-31 | 2021-12-01 | Nantkwest, Inc. | ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNITIES BY CD19 CAR EXPRESSING NK CELLS |
| CN113164521A (zh) * | 2018-11-26 | 2021-07-23 | 免疫生物公司 | 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞 |
| EP3938495A4 (en) | 2019-03-15 | 2023-04-26 | Nantcell, Inc. | RECOMBINANT ERIL-15 NK CELLS |
| US12085571B2 (en) | 2019-06-13 | 2024-09-10 | Immunitybio, Inc. | Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags |
| CA3148608A1 (en) * | 2019-07-26 | 2021-02-04 | Immunitybio, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| AU2020387167B2 (en) * | 2019-11-20 | 2024-10-24 | Immunitybio, Inc. | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
| CN113646435A (zh) * | 2019-12-09 | 2021-11-12 | 南克维斯特公司 | 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| KR20230153529A (ko) * | 2021-02-19 | 2023-11-06 | 프리트 엠. 쇼드하리 | 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체 |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| WO2024064824A2 (en) | 2022-09-21 | 2024-03-28 | Yale University | Compositions and methods for identification of membrane targets for enhancement of nk cell therapy |
| WO2025158400A1 (en) | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
| US20250298030A1 (en) * | 2024-03-20 | 2025-09-25 | Immunitybio, Inc. | Compositions and Methods for NK-92 Cells Expressing Native CD16 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE323756T1 (de) | 1997-04-30 | 2006-05-15 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| US7583797B2 (en) * | 2000-07-10 | 2009-09-01 | Broadcom Corporation | Single ended analog front end |
| ATE483472T1 (de) * | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| JP2008505071A (ja) * | 2004-07-02 | 2008-02-21 | アヴァリス・アクチエボラーグ | 細胞を遺伝学的に活性化する方法、および、該細胞の使用 |
| AU2005277831B2 (en) * | 2004-07-10 | 2012-11-22 | The Institute For Cancer Research | Genetically modified human natural killer cell lines |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| RU2715038C2 (ru) * | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| US9078488B1 (en) * | 2014-09-30 | 2015-07-14 | Nike, Inc. | Article of footwear incorporating a lenticular knit structure |
| CN117379460A (zh) * | 2015-03-27 | 2024-01-12 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
-
2016
- 2016-03-25 CN CN202311097228.2A patent/CN117379460A/zh active Pending
- 2016-03-25 US US15/529,848 patent/US10456420B2/en active Active
- 2016-03-25 KR KR1020227036402A patent/KR102751730B1/ko active Active
- 2016-03-25 CA CA2977423A patent/CA2977423A1/en active Pending
- 2016-03-25 IL IL287051A patent/IL287051B/en unknown
- 2016-03-25 IL IL301331A patent/IL301331A/en unknown
- 2016-03-25 CN CN201680019087.4A patent/CN107427578A/zh active Pending
- 2016-03-25 HK HK18109327.5A patent/HK1249854A1/zh unknown
- 2016-03-25 KR KR1020177030593A patent/KR102460387B1/ko active Active
- 2016-03-25 JP JP2017550603A patent/JP6748105B2/ja active Active
- 2016-03-25 KR KR1020257000202A patent/KR20250009013A/ko active Pending
- 2016-03-25 CN CN202210150391.XA patent/CN114533867A/zh active Pending
- 2016-03-25 EP EP16773863.2A patent/EP3273993A4/en active Pending
- 2016-03-25 CN CN202110908609.9A patent/CN113604435A/zh active Pending
- 2016-03-25 IL IL254214A patent/IL254214B2/en unknown
- 2016-03-25 WO PCT/US2016/024318 patent/WO2016160602A2/en not_active Ceased
- 2016-03-25 AU AU2016243120A patent/AU2016243120B2/en active Active
- 2016-03-25 IL IL294982A patent/IL294982B2/en unknown
- 2016-03-25 HK HK18106805.2A patent/HK1247117A1/zh unknown
-
2019
- 2019-08-15 US US16/541,847 patent/US10736921B2/en active Active
-
2020
- 2020-06-17 US US16/903,882 patent/US11000550B2/en active Active
- 2020-08-06 JP JP2020133495A patent/JP7000512B2/ja active Active
-
2021
- 2021-03-30 US US17/217,839 patent/US11207350B2/en active Active
- 2021-11-09 AU AU2021266225A patent/AU2021266225B2/en active Active
- 2021-11-18 US US17/530,211 patent/US12384852B2/en active Active
- 2021-12-23 JP JP2021208864A patent/JP7328314B2/ja active Active
-
2023
- 2023-08-03 JP JP2023126658A patent/JP7557704B2/ja active Active
-
2024
- 2024-08-28 JP JP2024146060A patent/JP7766151B2/ja active Active
-
2025
- 2025-04-11 AU AU2025202587A patent/AU2025202587A1/en active Pending
- 2025-07-17 US US19/272,876 patent/US20250340664A1/en active Pending
- 2025-10-27 JP JP2025180073A patent/JP2026021400A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510881A5 (https=) | ||
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Raghani et al. | Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies | |
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| CN107709548B (zh) | 用于增强治疗性免疫细胞的功效的方法 | |
| EP2513146B1 (en) | Antibodies against ror1 capable of inducing cell death of cll | |
| Bhojwani et al. | Relapsed childhood acute lymphoblastic leukaemia | |
| JP2018517415A5 (https=) | ||
| JP2019511222A5 (https=) | ||
| JP2017506217A5 (https=) | ||
| JP2016520074A5 (https=) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2009541492A5 (https=) | ||
| JP2021528047A5 (https=) | ||
| JP2019507582A5 (https=) | ||
| IL303269A (en) | Genetically engineered cells and uses thereof | |
| JP2014528696A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| TW201110981A (en) | Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone | |
| CA3189137A1 (en) | Methods and compositions for stimulating gamma delta t cells | |
| WO2016176756A1 (en) | Nk cells and antibodies for cancer treatment | |
| JP2018506287A5 (https=) | ||
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| Schultz et al. | New developments in immunotherapy for pediatric solid tumors | |
| JP2021525067A5 (https=) |